M: Metastasis; N: Node; T: Tumor. Data from [21]. Neuroendocrine tumors have demonstrated an increase in incidence and prevalence over the past decades, partly due to increased awareness ...

2 Typically, carcinoid syndrome is characterized by attacks ... agents most widely used to treat metastatic neuroendocrine tumors. Our experience suggests that fluoropyrimidines and anthracyclines ...

Carcinoid syndrome and carcinoid heart disease ... flushing and upper abdominal pain was referred to the neuroendocrine tumor unit by his oncologist. He had experienced a weight loss of 10 ...

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.

Carcinoid tumors are neoplasms that arise from neuroendocrine cells throughout ... Manifestations of the carcinoid syndrome include the "classic" triad of cutaneous flushing, diarrhea, and ...

The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

clinical director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute, said in a statement in September.

Clinical Director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute. "It was encouraging to see that ...

Jennifer Chan, MD, MPH, discussed outcomes of treating neuroendocrine tumors (NETs) with cabozantinib depending on whether they were pancreatic NETs or extrapancreatic NETs.